Top

International Ophthalmology

Published in:

01-12-2021 | Refractive Errors | Original Paper

Comparison of effects of tamsulosin and silodosin on subfoveal choroidal thickness and pupil size diameters in patients with prostatic hyperplasia

Authors: Hatice Selen Kanar, Mahmut Taha Olcucu, Ibrahim Ozdemir

Published in: International Ophthalmology | Issue 12/2021

Abstract

Purpose

To compare the effects of selective α-1 adrenoceptor antagonists on subfoveal choroidal thickness (SFCT) and pupil diameter size (PDS).

Methods

This prospective study included 87 patients diagnosed with benign prostatic hyperplasia who were treated with tamsulosin hydrochloride (n = 41) or silodosin (n = 46). SFCT measurements were obtained using spectral domain optic coherence tomography (SD-OCT), and PDS measurements were obtained under mesopic, photopic and scotopic conditions using a photography-based topography system. SFCT and PDS were evaluated at baseline and 3-, 6- and 12-mo follow-ups.

Results

The initial mean SFCT was 270.53 ± 21.48 µm in tamsulosin group and 271.95 ± 24. 73 in silodosin group (P = 0.078). There was no statistically significant change in SFCT at the 3-mo visit. At the 6-mo follow-up, the mean SFCT was 281.34 ± 22.09 µm in tamsulosin group and 272.5 ± 22.4 µm in silodosin group. At the 12th month, the mean SFCT in tamsulosin group was 290.80 ± 17.27 µm, and it was 270.80 ± 13.14 µm in silodosin group. There was statistically significant difference in at 6th and 12-mo visits (P = 0.014 and P = 0.00). During the follow-up, both drugs induced a similar significant decrease in PDS under all conditions.

Conclusions

Tamsulosin hydrochloride caused a significant increase in SFCT. In contrast, SFCT did not increase in silodosin group. The decreases in PDS achieved using both drugs were similar. This should be kept in mind when choroidal disease and its response to treatment are followed by CT imaging.

Lokeshwar SD, Harper BT, Webb E, Jordan A, Dykes TA, Neal DE Jr et al (2019) Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol 8(5):529–539. https://doi.org/10.21037/tau.2019.10.01 (PubMed PMID: 31807429)CrossRefPubMedPubMedCentral

Alcaraz A, Carballido-Rodríguez J, Unda-Urzaiz M, Medina-López R, Ruiz-Cerdá JL, Rodríguez-Rubio F et al (2016) Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment—the QUALIPROST study. Int Urol Nephrol 48(5):645–656CrossRef

Erkoç M, Beşiroğlu H (2020) Comparison of bipolar TURP and monopolar TURP patients who underwent surgery due to benign prostatic hyperplasia. Eur Arc Med Res 36(1):8–11CrossRef

Yonguc T, Sen V, Bozkurt HI, Aydin ME, Polat S, Yarimoglu S (2019) Impact of chronic constipation on lower urinary tract symptoms and uroflowmetry parameters in men. J Urolo Surg 6(4):308–313. https://doi.org/10.4274/jus.galenos.2019.2612(PubMedPMID:WOS:000501997300007)CrossRef

Aydogan TB, Kaya E, Gazel E, Yalcin S, Aybal HC, Tunc L (2019) Impact of metabolic syndrome on pre- and postoperative parameters in patients undergoing a HoLEP surgery. Turkish J Urol 45:98–103. https://doi.org/10.5152/tud.2019.88027 (PubMedPMID:WOS:000502637300017)CrossRef

Gürbüz C, Drake MJ (2019) Where can urodynamic testing help assess male lower urinary tract symptoms? Turkish J Urol 45(3):157CrossRef

Verim L, Yıldırım A, Peltekoğlu E, Başok EK, Keskin SK, Çanakcı C (2015) Evaluation of the lower urinary tract symptoms and erectile dysfunction with uroflowmetry, IPSS and IIEF questioniares. J Urol Surg 2(2):75–80CrossRef

Yap TL, Brown C, Cromwell DA, Van Der Meulen J, Emberton M (2009) The impact of self-management of lower urinary tract symptoms on frequency-volume chart measures. BJU Int 104(8):1104–1108. https://doi.org/10.1111/j.1464-410X.2009.08497.xCrossRefPubMed

Bishr M, Boehm K, Trudeau V, Tian Z, Dell’Oglio P, Schiffmann J et al (2016) Medical management of benign prostatic hyperplasia: results from a population-based study. Can Urol Assoc J 10(1–2):55–59. https://doi.org/10.5489/cuaj.3058 (PubMed PMID: 26977208)CrossRefPubMedPubMedCentral

10.

Michel MC (2010) The Forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: α-blockers in the treatment of male voiding dysfunction—How do they work and why do they differ in tolerability? J Pharmacol Sci 112(2):151–157. https://doi.org/10.1254/jphs.09R15FMCrossRefPubMed

11.

Oelke M, Gericke A, Michel MC (2014) Cardiovascular and ocular safety of α1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. Expert Opin Drug Saf 13(9):1187–1197. https://doi.org/10.1517/14740338.2014.936376CrossRefPubMed

12.

Suzuki F, Taniguchi T, Nakamura S, Akagi Y, Kubota C, Satoh M et al (2002) Distribution of alpha-1 adrenoceptor subtypes in RNA and protein in rabbit eyes. Br J Pharmacol 135(3):600–608. https://doi.org/10.1038/sj.bjp.0704503 (PubMed PMID: 11834607)CrossRefPubMedPubMedCentral

13.

Lunacek A, Mohamad Al-Ali B, Radmayr C, Weber M, Horninger W, Findl O et al (2018) Ten years of intraoperative floppy iris syndrome in the era of α-blockers. Cent European J Urol 71(1):98–104. https://doi.org/10.5173/ceju.2017.1234 (PubMed PMID: 29732214)CrossRefPubMed

14.

Sezer T, Altınışık M, Koytak İA, Özdemir MH (2016) The choroid and optical coherence tomography. Turk J Ophthalmol. 46(1):30–7. https://doi.org/10.4274/tjo.10693 (PubMed PMID: 27800255)CrossRefPubMedPubMedCentral

15.

Shibata K, Foglar R, Horie K, Obika K, Sakamoto A, Ogawa S et al (1995) KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol 48(2):250–258PubMed

16.

Chang DF, Campbell JR (2005) Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 31(4):664–673. https://doi.org/10.1016/j.jcrs.2005.02.027CrossRefPubMed

17.

Chatterjee S, Agrawal D (2017) Silodosin-associated intraoperative floppy iris syndrome. Indian J Ophthalmol 65(6):538–539. https://doi.org/10.4103/ijo.IJO_704_16CrossRefPubMedPubMedCentral

18.

Ipekci T, Akin Y, Hoscan B, Tunckiran A (2015) Intraoperative floppy iris syndrome associated with silodosin. Acta Ophthalmologica 93(4):e306-e. https://doi.org/10.1111/aos.12549CrossRef

19.

Goseki T, Ishikawa H, Ogasawara S, Mashimo K, Nemoto N, Taguchi Y et al (2012) Effects of tamsulosin and silodosin on isolated albino and pigmented rabbit iris dilators: possible mechanism of intraoperative floppy-iris syndrome. J Cataract Refract Surg 38(9):1643–1649. https://doi.org/10.1016/j.jcrs.2012.05.025CrossRefPubMed

20.

Patil PN (2004) Parameters of drug antagonism: re-examination of two modes of functional competitive drug antagonism on intraocular muscles. J Pharm Pharmacol 56(8):1045–1053. https://doi.org/10.1211/0022357043978CrossRefPubMed

21.

Dogan M, Kutluksaman B, Keles I, Karalar M, Halat AO (2017) The effects of systemic alfuzosin and tamsulosin hydrochloride on choroidal thickness and pupil diameter sizes in cases with benign prostatic hyperplasia. Curr Eye Res 42(12):1638–1643. https://doi.org/10.1080/02713683.2017.1359306CrossRefPubMed

22.

Sari E, Sogutlu Sari E, Yazici A, Koç A, Bulbul E, Koytak A et al (2015) The effect of systemic tamsulosin hydrochloride on choroidal thickness measured by enhanced depth imaging spectral domain optical coherence tomography. Curr Eye Res 40(10):1068–1072. https://doi.org/10.3109/02713683.2014.971935CrossRefPubMed

23.

Nickla DL, Wallman J (2010) The multifunctional choroid. Prog Retin Eye Res 29(2):144–168. https://doi.org/10.1016/j.preteyeres.2009.12.002 (PubMed PMID: 20044062; PubMed Central PMCID: PMC2913695)CrossRefPubMed

24.

Ölçücü MT, Teke K, Yildirim K, Toğaç M, Işık B, Yilmaz YC (2020) Comparision effects of solifenacin, darifenacin, propiverine on ocular parameters in eyes: a prospective study. Int Braz J Urol 46(2):185–193CrossRef

25.

Reiner A, Zagvazdin Y, Fitzgerald MEC (2003) Choroidal blood flow in pigeons compensates for decreases in arterial blood pressure. Exp Eye Res 76(3):273–282. https://doi.org/10.1016/S0014-4835(02)00316-0CrossRefPubMed

26.

Bouteleux V, Kodjikian L, Mendes M, Agard E, Machkour-Bentaleb Z, El-Chehab H et al (2019) Increased choroidal thickness: a new feature to monitor age-related macular degeneration recurrence. Graefes Arch Clin Exp Ophthalmol 257(4):699–707. https://doi.org/10.1007/s00417-018-04216-8CrossRefPubMed

27.

Chen Y, Palczewska G, Mustafi D, Golczak M, Dong Z, Sawada O et al (2013) Systems pharmacology identifies drug targets for Stargardt disease-associated retinal degeneration. J Clin Inves 123(12):5119–34. https://doi.org/10.1172/jci69076 (PubMed PMID: 24231350)CrossRef

28.

Orban T, Leinonen H, Getter T, Dong Z, Sun W, Gao S et al (2018) A combination of G protein-coupled receptor modulators protects photoreceptors from degeneration. J Pharmacol Exp Ther 364(2):207–20. https://doi.org/10.1124/jpet.117.245167 (PubMed PMID: 29162627)CrossRefPubMedPubMedCentral

Title: Comparison of effects of tamsulosin and silodosin on subfoveal choroidal thickness and pupil size diameters in patients with prostatic hyperplasia
Authors: Hatice Selen Kanar
Mahmut Taha Olcucu
Ibrahim Ozdemir
Publication date: 01-12-2021
Publisher: Springer Netherlands
Keywords: Refractive Errors
Benign Prostatic Hypertrophy
Benign Prostatic Hypertrophy
Tamsulosin
Published in: International Ophthalmology / Issue 12/2021
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-021-01961-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Comparison of effects of tamsulosin and silodosin on subfoveal choroidal thickness and pupil size diameters in patients with prostatic hyperplasia

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2021

Choroidal vascularity index in pseudoexfoliative glaucoma

Post-remission retinal microvascular and choroidal thickness changes in eyes with Behḉet’s disease posterior uveitis: an OCTA longitudinal study

Optical coherence tomography angiography evaluation of the effects of phacoemulsification cataract surgery on macular hemodynamics in Chinese normal eyes

Endophthalmitis: a bibliographic review

Descemet’s membrane area and posterior corneal power may predict the Descemet membrane folds after deep anterior lamellar keratoplasty in patients with advanced keratoconus

Evaluation of migraine patients with optical coherence tomography angiography